Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 3
Submit an article Journal homepage
2,419
Views
38
CrossRef citations to date
0
Altmetric
Original Research

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment

Chiara RigantiDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Marcello Francesco LinguaDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Iris Chiara SalaroglioDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Chiara FalcomatàDepartment of Oncology, University of Torino, Torino, Italy;Candiolo Cancer Institute – FPO, IRCCS, Candiolo, ItalyORCID Iconhttp://orcid.org/0000-0001-9269-2582View further author information
ORCID Icon,
Luisella RighiPathology Unit, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, ItalyView further author information
,
Deborah MorenaDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Francesca PiccaDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Daniele OddoDepartment of Oncology, University of Torino, Torino, Italy;Candiolo Cancer Institute – FPO, IRCCS, Candiolo, ItalyORCID Iconhttp://orcid.org/0000-0001-6179-1668View further author information
ORCID Icon,
Joanna KopeckaDepartment of Oncology, University of Torino, Torino, ItalyView further author information
,
Monica PradottoThoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, ItalyView further author information
,
Roberta LibenerPathology Division, S. Antonio and Biagio Hospital, Alessandria, ItalyView further author information
,
Sara OrecchiaPathology Division, S. Antonio and Biagio Hospital, Alessandria, ItalyView further author information
,
Paolo BironzoThoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, ItalyView further author information
,
Valentina ComunanzaDepartment of Oncology, University of Torino, Torino, Italy;Candiolo Cancer Institute – FPO, IRCCS, Candiolo, ItalyORCID Iconhttp://orcid.org/0000-0002-0695-6420View further author information
ORCID Icon,
Federico BussolinoDepartment of Oncology, University of Torino, Torino, Italy;Candiolo Cancer Institute – FPO, IRCCS, Candiolo, ItalyView further author information
,
Silvia NovelloThoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, ItalyView further author information
,
Giorgio Vittorio ScagliottiThoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, ItalyORCID Iconhttp://orcid.org/0000-0001-6646-958XView further author information
ORCID Icon,
Federica Di NicolantonioDepartment of Oncology, University of Torino, Torino, Italy;Candiolo Cancer Institute – FPO, IRCCS, Candiolo, ItalyORCID Iconhttp://orcid.org/0000-0001-9618-2010View further author information
ORCID Icon &
Riccardo TaulliDepartment of Oncology, University of Torino, Torino, ItalyCorrespondence[email protected]
View further author information
 show all
Article: e1398874 | Received 05 Jul 2017, Accepted 24 Oct 2017, Published online: 27 Nov 2017

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2019) Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology 8:11.
Read now

Articles from other publishers (37)

Seongmin Kim, Seung Hyuck Jeon, Min Guk Han, Mi Hyun Kang & In Ah Kim. (2023) BRD4 Inhibition Enhances the Antitumor Effects of Radiation Therapy in a Murine Breast Cancer Model. International Journal of Molecular Sciences 24:17, pages 13062.
Crossref
Xiaotian He, Dechang Zhao, Xuewen Zhang, Yiyang Ma, Rusi Zhang, Zirui Huang, Gongming Wang, Guangran Guo, Weidong Wang, Yingsheng Wen & Lanjun Zhang. (2023) Intrinsic Immunogenic Tumor Cell Death Subtypes Delineate Prognosis and Responsiveness to Immunotherapy in Lung Adenocarcinoma. Biology 12:6, pages 808.
Crossref
Madison E Carelock, Rohan P Master, Myung-Chul Kim, Zeng Jin, Lei Wang, Chandra K Maharjan, Nan Hua, Umasankar De, Ryan Kolb, Yufeng Xiao, Daiqing Liao, Guangrong Zheng & Weizhou Zhang. (2023) Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy. Life Medicine 2:3.
Crossref
Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M. Haikala, Olli Kallioniemi, Mikko I. Mäyränpää & Ilkka Ilonen. (2023) Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing. Lung Cancer 178, pages 213-219.
Crossref
Zheng Liu, Rui Wan, Hua Bai & Jie Wang. (2023) Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy. Frontiers in Immunology 14.
Crossref
Jiawei Guo, Qingquan Zheng & Yong Peng. (2023) BET proteins: Biological functions and therapeutic interventions. Pharmacology & Therapeutics 243, pages 108354.
Crossref
Feng-Ming Tien, Hsuan-Hsuan Lu, Shu-Yung Lin & Hsing-Chen Tsai. (2023) Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. Journal of Biomedical Science 30:1.
Crossref
Juliette Humeau, Julie Le Naour, Guido Kroemer & Jonathan G. Pol. 2023.
Marta Matuszewska, Magdalena Cieślik, Anna Wilkaniec, Marcin Strawski & Grzegorz A. Czapski. (2022) The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer’s Disease. International Journal of Molecular Sciences 24:1, pages 13.
Crossref
Iris Chiara Salaroglio, Dimas Carolina Belisario, Paolo Bironzo, Preeta Ananthanarayanan, Luisa Ricci, Sabrina Digiovanni, Simona Fontana, Francesca Napoli, Alberto Sandri, Chiara Facolmatà, Roberta Libener, Valentina Comunanza, Federica Grosso, Elena Gazzano, Francesco Leo, Riccardo Taulli, Federico Bussolino, Luisella Righi, Mauro Giulio Papotti, Silvia Novello, Giorgio Vittorio Scagliotti, Chiara Riganti & Joanna Kopecka. (2022) SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Vera E. van der Noord, Bob van de Water & Sylvia E. Le Dévédec. (2022) Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. Cancers 14:18, pages 4353.
Crossref
Baiwen Chen, Jiajia Hu, Xianting Hu, Huifang Chen, Rujuan Bao, Yatao Zhou, Youqiong Ye, Meixiao Zhan, Wei Cai, Huabin Li & Hua-Bing Li. (2022) DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nature Communications 13:1.
Crossref
Dixita Ishani Viswanath, Hsuan-Chen Liu, David P. Huston, Corrine Ying Xuan Chua & Alessandro Grattoni. (2022) Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. Biomaterials 280, pages 121297.
Crossref
Eugenia Lorenzini, Alessia Ciarrocchi & Federica Torricelli. (2021) Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. Journal of Clinical Medicine 10:11, pages 2470.
Crossref
Dario P. Anobile, Paolo Bironzo, Francesca Picca, Marcello F. Lingua, Deborah Morena, Luisella Righi, Francesca Napoli, Mauro G. Papotti, Alessandra Pittaro, Federica Di Nicolantonio, Chiara Gigliotti, Federico Bussolino, Valentina Comunanza, Francesco Guerrera, Alberto Sandri, Francesco Leo, Roberta Libener, Pablo Aviles, Silvia Novello, Riccardo Taulli, Giorgio V. Scagliotti & Chiara Riganti. (2021) Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers 13:10, pages 2332.
Crossref
Heleen H. Van Acker, Shixin Ma, Tommaso Scolaro, Susan M. Kaech & Massimiliano Mazzone. (2021) How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. Trends in Immunology 42:5, pages 401-417.
Crossref
Elena Jachetti, Sabina Sangaletti, Claudia Chiodoni, Roberto Ferrara & Mario P. Colombo. (2021) Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. Cellular Immunology 362, pages 104301.
Crossref
Martina Schiavello, Elena Gazzano, Loredana Bergandi, Francesca Silvagno, Roberta Libener, Chiara Riganti & Elisabetta Aldieri. (2021) Identification of Redox-Sensitive Transcription Factors as Markers of Malignant Pleural Mesothelioma. Cancers 13:5, pages 1138.
Crossref
Nian Wang, Runliu Wu, Daolin Tang & Rui Kang. (2021) The BET family in immunity and disease. Signal Transduction and Targeted Therapy 6:1.
Crossref
Jeremy To, Doug Quackenbush, Emily Rowell, Lilin Li, Connor Reed, Frederick Lo & Shane R. Horman. (2021) RETRACTED ARTICLE: A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell function. Communications Biology 4:1.
Crossref
Yehui Shi, Ying Fu, Xin Zhang, Gang Zhao, Yuan Yao, Yan Guo, Gang Ma, Shuai Bai & Hui Li. (2020) Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunology, Immunotherapy 70:1, pages 61-73.
Crossref
Dean A. Fennell. 2021. Malignant Pleural Mesothelioma. Malignant Pleural Mesothelioma 279 289 .
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel & Guido Kroemer. (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology 17:12, pages 725-741.
Crossref
Simon J. Hogg, Paul A. Beavis, Mark A. Dawson & Ricky W. Johnstone. (2020) Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery 19:11, pages 776-800.
Crossref
Filippo Spriano, Anastasios Stathis & Francesco Bertoni. (2020) Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacology & Therapeutics 215, pages 107631.
Crossref
Yi-Ru Chen, Su-Shan Ouyang, Yan-Ling Chen, Ping Li, Hui-Wen Xu & Sen-Lin Zhu. (2020) BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma. Aging 12:17, pages 17541-17567.
Crossref
Lorenzo Galluzzi, Ilio Vitale, Sarah Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buqué Martinez, Timothy A Chan, George Coukos, Sandra Demaria, Eric Deutsch, Dobrin Draganov, Richard L Edelson, Silvia C Formenti, Jitka Fucikova, Lucia Gabriele, Udo S Gaipl, Sofia R Gameiro, Abhishek D Garg, Encouse Golden, Jian Han, Kevin J Harrington, Akseli Hemminki, James W Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L Kaufman, Oliver Kepp, Guido Kroemer, Juan Jose Lasarte, Sherene Loi, Michael T Lotze, Gwenola Manic, Taha Merghoub, Alan A Melcher, Karen L Mossman, Felipe Prosper, Øystein Rekdal, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Mark J Smyth, Radek Spisek, John Stagg, Bryan E Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan W van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano & Francesco M Marincola. (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for ImmunoTherapy of Cancer 8:1, pages e000337.
Crossref
Lu Zhao, Pengchong Li, Li Zhao, Miao Wang, Dongdong Tong, Zilin Meng, Qian Zhang, Qing Li & Fenghe Zhang. (2019) Expression and clinical value of PD‐L1 which is regulated by BRD4 in tongue squamous cell carcinoma. Journal of Cellular Biochemistry 121:2, pages 1855-1869.
Crossref
Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li & Fenghe Zhang. (2019) BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma. International Immunopharmacology 76, pages 105921.
Crossref
Guillaume P. Andrieu, Jordan S. Shafran, Charlotte L. Smith, Anna C. Belkina, Allison N. Casey, Naser Jafari & Gerald V. Denis. (2019) BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Letters 465, pages 45-58.
Crossref
Carlo Follo, Yao Cheng, William G. Richards, Raphael Bueno & V. Courtney Broaddus. (2019) Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma. Molecular Carcinogenesis 58:10, pages 1754-1769.
Crossref
Kathleen Puttmann, Megan Duggan, Amir Mortazavi, Dayssy Alexandra Diaz, William E. Carson III & Debasish Sundi. (2019) The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy. Bladder Cancer 5:2, pages 103-114.
Crossref
Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Ruikang Tao, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae-Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kaixiong Tao & Guang Peng. (2019) The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Molecular Cancer Therapeutics 18:8, pages 1439-1450.
Crossref
Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muamera Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo A. Morales, Joseph R. Garlich & Donald L. Durden. (2019) SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Molecular Cancer Therapeutics 18:6, pages 1036-1044.
Crossref
Elisabeth Digifico, Cristina Belgiovine, Alberto Mantovani & Paola Allavena. 2019. Mesothelioma. Mesothelioma 69 84 .
Pei Zhang, Jinzhong Liu, Wenlu Li, Shanshan Li & Xinguang Han. (2018) Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD ‐L1 . Cancer Medicine 7:7, pages 3178-3187.
Crossref
Joanna Kopecka, Iris C. Salaroglio, Luisella Righi, Roberta Libener, Sara Orecchia, Federica Grosso, Vladan Milosevic, Preeta Ananthanarayanan, Luisa Ricci, Enrica Capelletto, Monica Pradotto, Francesca Napoli, Massimo Di Maio, Silvia Novello, Menachem Rubinstein, Giorgio V. Scagliotti & Chiara Riganti. (2018) Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung Cancer 120, pages 34-45.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.